“…5HT3RA 5HT3RAs are recommended by guidelines for CINV prophylaxis in autologous SCT, as well as for highly emetogenic drugs as part of a three-drug combination (aprepitant + 5HT3RA + dexamethasone) [4,8,9]. In the setting of HDMel, palonosetron was investigated in five trials [7,11,13,15,20], granisetron in three trials [12,17,19], and ondansetron in three trials [14,16,18]. The efficacy of different 5HT3RA drugs was not evaluated in the setting of HDMel; therefore, they should perhaps be considered equivalent in terms of efficacy for CINV prevention.…”